|
December 17, 2012
FLEXION'S FX006 ACHIEVES PROLONGED THERAPEUTIC CONCENTRATIONS IN JOINTS OF OSTEOARTHRITIS PATIENTS
December 14, 2012
BIOTIE: SELINCRO(TM) (NALMEFENE) RECEIVES POSITIVE OPINION FOR APPROVAL IN THE EUROPEAN UNION
December 12, 2012
THE MEDICINES COMPANY AGREES TO ACQUIRE INCLINE THERAPEUTICS, INC.
December 11, 2012
BIOTIE'S TOZADENANT (SYN115) MEETS PRIMARY AND MULTIPLE SECONDARY ENDPOINTS IN PHASE 2B STUDY IN PARKINSON'S DISEASE
December 4, 2012
FLEXION THERAPEUTICS SECURES $20 MILLION IN SERIES B FINANCING
November 13, 2012
PEARL THERAPEUTICS RAISES $65 MILLION SERIES D TO START PT003 PHASE 3
November 4, 2012
TAKEDA TO ACQUIRE ENVOY THERAPEUTICS, INC.
October 11, 2012
C. ROBERT KIDDER JOINS BOARD OF DIRECTORS OF WILDCAT DISCOVERY TECHNOLOGIES, INC.
October 5, 2012
KALOBIOS PHARMACEUTICALS FILES REGISTRATION STATEMENT FOR PROPOSED IPO
October 4, 2012
RUIYI (FORMERLY ANAPHORE) AND ARGEN-X ANNOUNCE EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR ARGX-109, A NOVEL ANTI-IL-6 ANTIBODY
October 4, 2012
ANAPHORE ANNOUNCES NAME CHANGE TO RUIYI AND NEW ADDITIONS TO SHANGHAI MANAGEMENT TEAM
September 26, 2012
WILDCAT DISCOVERY TECHNOLOGIES ENTERS JOINT DEVELOPMENT AGREEMENT WITH JAPAN'S ASAHI KASEI CORP. FOR RECHARGEABLE BATTERY TECHNOLOGY
September 18, 2012
IGENICA APPOINTS MARY HAAK-FRENDSCHO, PH.D., AS CHIEF EXECUTIVE OFFICER
September 14, 2012
CYSTIC FIBROSIS FOUNDATION THERAPEUTICS AND PULMATRIX INITIATE COLLABORATION TO ACCELERATE PUR118 IN THE TREATMENT OF CYSTIC FIBROSIS
September 13, 2012
PEARL THERAPEUTICS COMPLETES PHASE 2B STUDY OF GLYCOPYRROLATE, DEFINES DOSE-RESPONSE CURVE AND IDENTIFIES OPTIMAL DOSE OF PT001
September 11, 2012
KALOBIOS INITIATES PHASE 2 STUDY WITH KB003 HUMANEERED™
MONOCLONAL ANTIBODY IN SEVERE ASTHMA
September 7, 2012
LUNDBECK HAS MADE EUR 10 MILLION EQUITY INVESTMENT IN BIOTIE AND THE PARTIES AMEND THE SELINCRO LICENSING AGREEMENT REGARDING TERRITORIES OUTSIDE THE EU AND US
September 7, 2012
BIOTIE HAS COMPLETED A DIRECTED SHARE ISSUE OF EUR 20 MILLION TO INSTITUTIONAL AND STRATEGIC INVESTORS
September 6, 2012
KALOBIOS COMPLETES DEBT FINANCING OF UP TO $15 MILLION - DEBT FINANCING FOLLOWS $20.25 MILLION IN GROSS EQUITY RAISED IN SECOND QUARTER
August 27, 2012
GENOMEWEB/PROTEOMONITOR ARTICLE: NOLAN LAB PROFILES SMALL-MOLECULE INHIBITORS USING NEW MULTIPLEXING METHOD FOR DVS SCIENCES' CYTOF
August 24, 2012
NOVIRA THERAPEUTICS SECURES $23 MILLION SERIES A FINANCING TO ADVANCE DEVELOPMENT OF ANTIVIRALS FOR TREATMENT OF CHRONIC HEPATITIS B AND HIV INFECTIONS
August 15, 2012
RELYPSA ANNOUNCES $80 MILLION PRIVATE FINANCING TRANSACTION
August 3, 2012
ATTEROCOR LAUNCHES INNOVATIVE COMPANY FOCUSED ON ACCELERATED DEVELOPMENT OF TREATMENT FOR ADRENAL CANCER; SECURES $16 MILLION SERIES A FINANCING
July 10, 2012
JEFF COOPER JOINS KALOBIOS AS CHIEF FINANCIAL OFFICER
July 5, 2012
BIOTIE COMPLETES ENROLLMENT IN PHASE 2B TRIAL OF TOZADENANT IN PARKINSON'S DISEASE
June 25, 2012
TELEFLEX ACQUIRES INNOVATIVE TECHNOLOGY TO REDUCE BIOLOGICAL FORMATION ON MEDICAL DEVICES
June 25, 2012
KALOBIOS' KB001 DEMONSTRATES SAFETY, POTENTIAL AS NEW APPROACH TO PREVENTING PSEUDOMONAS VENTILATOR ASSOCIATED PNEUMONIA
June 18, 2012
PATRICIA SCHELLER NAMED CEO OF VIVEVE, INC.
June 18, 2012
AMBRX COLLABORATES WITH MERCK TO DESIGN AND DEVELOP BIOLOGIC DRUG CONJUGATES
June 12, 2012
IGENICA CLOSES $33 MILLION IN SERIES C FUNDING
June 7, 2012
KALOBIOS APPOINTS NÉSTOR MOLFINO AS CHIEF MEDICAL OFFICER
May 30, 2012
FLEXION'S LEAD OSTEOARTHRITIS DRUG CANDIDATE DEMONSTRATES SIGNIFICANT, PROLONGED IMPROVEMENT IN PAIN AND FUNCTION IN PHASE 2 TRIAL
May 28, 2012
THE VIVEVE SYSTEM RECEIVES HEALTH CANADA MEDICAL DEVICE LICENSE TO NON-SURGICALLY TREAT VAGINAL LAXITY FOLLOWING CHILDBIRTH
May 21, 2012
PEARL THERAPEUTICS RECEIVES TIE50 AWARD FROM GLOBAL ENTREPRENEURSHIP NETWORK
May 15, 2012
ACHAOGEN ANNOUNCES ALL OBJECTIVES MET IN PHASE 2 PLAZOMICIN COMPLICATED URINARY TRACT INFECTIONS STUDY AND START OF FIRST-IN-HUMAN STUDY WITH ACHN-975
May 15, 2012
WILDCAT DISCOVERY TECHNOLOGIES ARTICLE IN MAY/JUNE 2012 TECHNOLOGY REVIEW
May 14, 2012
PEARL THERAPEUTICS PHASE 2B TWICE-DAILY DOSING DATA SUGGEST MORNING AND EVENING BENEFIT OF PT003 IN PATIENTS WITH COPD
May 7, 2012
MICHAEL J. FOX FOUNDATION EXPANDS FUNDING TO ENVOY
April 27, 2012
WILDCAT DISCOVERY TECHNOLOGIES NAMED ONE OF TECHNOLOGY REVIEW'S 2012 TOP 50 MOST INNOVATIVE COMPANIES
March 22, 2012
ANAPHORE ANNOUNCES ACQUISITION OF RUIYI IN SHANGHAI CHINA FOR GPCR BIOLOGICS DRUG DISCOVERY PLATFORM
March 13, 2012
FLEXION ARTICLE: COULD THIS BE ORTHOPEDICS' FUTURE?, ORTHOPEDICS THIS WEEK, 8 (9)
March 5, 2012
DATA PRESENTED AT THE 2012 EUROPEAN CONGRESS OF PSYCHIATRY SHOWING THAT SELINCRO(TM) REDUCES TOTAL ALCOHOL CONSUMPTION BY TWO-THIRDS ON AVERAGE AFTER SIX MONTHS OF TREATMENT
March 1, 2012
BIOTIE SUCCESSFULLY COMPLETES IMAGING STUDY WITH SYN120 |
